Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P08069

UPID:
IGF1R_HUMAN

ALTERNATIVE NAMES:
Insulin-like growth factor I receptor

ALTERNATIVE UPACC:
P08069; B1B5Y2; Q14CV2; Q9UCC0

BACKGROUND:
Insulin-like growth factor 1 receptor (IGF1R) functions as a critical mediator of IGF1 actions, facilitating cell growth and survival. Its activation by IGF1 initiates a cascade of phosphorylation events, activating pathways like PI3K-AKT/PKB and Ras-MAPK, which are vital for cellular functions and survival, particularly in cancer cells.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Insulin-like growth factor 1 receptor could open doors to potential therapeutic strategies. Given its key role in diseases like Insulin-like growth factor 1 resistance, targeting IGF1R offers a promising avenue for developing treatments for growth disorders and cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.